To the full analysis
Torrent Pharmaceuticals stock: growth
TORNTPHARM.NSTorrent Pharmaceuticals reported $1.49B in revenue for fiscal 2026, up 23.5% on the prior year, up 12.1% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
13.3%
per year from 2007 to 2026, per share 13.3%
Earnings (Annual rate)
18%
per year from 2007 to 2026, per share 18%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2021 | since 2016 | since 2007 | |
|---|---|---|---|
| Revenue | 12.1% | 7.9% | 13.3% |
| Revenue per share | 12.1% | 7.9% | 13.3% |
| Earnings | 11.6% | 2.2% | 18.0% |
| Earnings per share | 11.6% | 2.2% | 18.0% |
| Free cash flow | 3.1% | −0.8% | no data |
| Free cash flow per share | 3.1% | −0.8% | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2007 | $138.05M | $9.94M | −$2.79M |
| 2008 | $144M | $14.31M | $12.04M |
| 2009 | $173.32M | $19.6M | $20.74M |
| 2010 | $194.82M | $24.57M | $14.55M |
| 2011 | $224.77M | $28.72M | $13.77M |
| 2012 | $275.59M | $30.19M | $35.83M |
| 2013 | $324.02M | $46M | −$14.82M |
| 2014 | $428.59M | $70.56M | $21.19M |
| 2015 | $486.67M | $79.82M | $60.33M |
| 2016 | $692.94M | $184.22M | $224.18M |
| 2017 | $602.89M | $99.23M | $55.9M |
| 2018 | $619.11M | $72.08M | $10.94M |
| 2019 | $793.11M | $46.37M | $120.66M |
| 2020 | $826.93M | $108.92M | $104.7M |
| 2021 | $838.22M | $133.06M | $178.09M |
| 2022 | $894.82M | $82.61M | $170.11M |
| 2023 | $1.01B | $132.35M | $190.68M |
| 2024 | $1.12B | $176.05M | $301.15M |
| 2025 | $1.2B | $203.14M | $209.81M |
| 2026 | $1.49B | $229.9M | $207.79M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = ₹94.0836)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Overvalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.